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Abstract  
BACKGROUND: Diabetes is diagnosed in 10-20% of patients with acute coronary syndrome (ACS) 
not known to be diabetics. Elevated blood glucose is an independent risk factor for cardiac events, 
regardless of presence of diabetes.  
AIM: Evaluating the prevalence of new-diagnosed DM among patients with ACS, and assessing the 
relationship between stress glycaemia and new diagnosed DM with in-hospital cardiac events.  
METHODS: Prospective observational study, in patients with ACS, in whom we analyzed 
parameters of glycemic metabolism, clinical data, and in-hospital cardiac events. We comparatively 
analyzed patients according to the HgbA1C and known DM in five groups: non-DM (< 5.6%), new 
pre-DM (5.6-6.5%), new DM (≥ 6.5%), controlled (<7%) and uncontrolled (≥7%) known DM.  
RESULTS: 150 patients, (93 male and 57 female) were included. Impaired glucose metabolism 
was detected in 44.5% of patients, 7.9% of whom were newly-diagnosed DM. The highest levels of 
stress glycaemia were found in new and uncontrolled known DM. The in-hospital event rate was 
20.7%, the mortality rate 7.3%, being the highest in new diagnosed and uncontrolled known DM 
patients.  
CONCLUSIONS: The prevalence of unknown DM was high among patients with ACS. Stress 
glycaemia and failure to achieve glycemic controlee, were an independent predictors of in-hospital 
cardiac events. 
 
 
Introduction 
 
Diabetes mellitus is increasing on a global 
level with an estimated prevalence around 12-14%. 
What is even more important, it is also estimated that 
one in every four hospitalized patients has known 
diabetes. Hyperglycemia in hospitalized patients is 
even more frequent [1]. 
The Study of Abdullatef et al. performed on 
Qatar population with acute coronary syndrome 
(ACS), refers that 45% of hospitalized patients without 
known DM were either with prediabetes, diabetes or 
stress hyperglycemia [2]. There are three possible 
causes for hyperglycemia in hospitalized patients: 
existing known diabetes, existing but unknown 
diabetes and stress hyperglycemia. Stress 
hyperglycemia is defined by ADA (American Diabetes 
Association) as an elevation of fasting glucose ≥ 7 
mmol/L, or 2-hour postprandial glucose ≥ 11 mmol/L, 
in a patient without evidence of previous diabetes. 
Glycosylated hemoglobin (HbA1c) value has been 
recommended to distinguish between patients with 
stress hyperglycemia and those with previously 
undiagnosed diabetes. HbA1c value ≥ 6.5% indicates 
pre-existing unrecognized diabetes, whereas HbA1c 
value < 6.5% indicates stress-induced hyperglycemia. 
The prevalence of stress hyperglycemia in critically ill 
patients varies between 30-40%, 10-15% of which 
have previously unrecognized diabetes. (3) Gornik et 
al. reported a prevalence of unrecognized diabetes 
among critically ill patients of 17% [4]. In the 
population of elderly patients hospitalized due to heart 
failure the prevalence of hyperglycemia was 44%, and 
41% in patients with acute coronary syndrome [5].  
Stress hyperglycemia has several means. 
Stress conditions such as surgery, trauma and acute 
illness increase the circulatory level of counter 
regulatory hormones (glucagon, cortisol, 
catecholamines) and pro-inflammatory cytokines and 
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they alter the effect of insulin on the hepar and on the 
skeletal muscle by increasing of the hepatic 
production of glucose and decreasing the peripheral 
utilization of glucose. Pro-inflammatory cytokines also 
increase the hepatic release of glucose and increase 
the insulin resistance in the hepar and in the skeletal 
muscle. Stress hyperglycemia in patients with 
diabetes type 2 involves a combination of insulin 
resistance and beta cell secretory defect [3]. 
 
The impact of hyperglycemia  
Patients with stress hyperglycemia have a 
higher mortality rate and longer hospitalization time in 
comparison with patients with known diabetes and 
with normoglycaemia. They have worse outcome in 
comparison with diabetic patients with a comparable 
degree of hyperglycemia. It depends on the 
underlying diagnose, risk of infection etc. Non-diabetic 
patients with stress hyperglycemia have 3.9 fold 
higher risk of death after myocardial infarction in 
comparison with normoglycaemic non-DM patients. 
The same finding is also evident in patients with 
stroke. Worse clinical status is evident in non-diabetic 
patients with stress hyperglycemia in comparison with 
diabetic patients [3, 6, 7]. 
The aim of this study was to evaluate the 
prevalence of new-diagnosed DM among patients with 
ACS, and assessing the relationship between stress 
glycaemia and new diagnosed DM with in-hospital 
cardiac events. 
 
 
Material and Methods 
 
This was a prospective observational study. 
Patients admitted to ICCU and treated for acute 
coronary syndrome-ACS (unstable angina-APNS, 
NSTEMI-myocardial infarction without ST-segment 
elevation and STEMI-myocardial infarction with ST-
segment elevation), were enrolled. All patients with 
confirmed ACS during the two month period were 
included. We analyzed glycemic parameters: blood 
glycaemia at admition (stress glycaemia), fasting 
plasma glycaemia the first morning after admition, 
glycaemia levels during the hospital treatment and 
HgbA1C.  
Demographic, clinical, left ventricular 
functional and angiographic data were obtained for all 
150 patients (pts.). We analyzed: body presence of 
risk factors and co-morbidities, basic biochemical 
variables (Hgb, BUN, creatinine, Na, K), lipid profile 
(Tg, HDL, LDL Hol, lpa), LV systolic and diastolic 
function, SINTAX score, TIMI flow before and after 
PCI procedure, duration of hospitalization (days) and 
in-hospital morbidity/ mortality: heart failure, malignant 
arrhythmias, early ischemic events, bleeding 
complications (CE) and cardiac death (CD).  
We used ADA (American Diabetes 
Association) 2015 Guidelines criteria for the diabetes 
definition (fasting plasma glycose (FPG) >7 mmoll/L, 
or random plasma glucose (RPG) >11.1 mmol/L, or 
HgbA1C >6.5%), and HgbA1C >5.6% for the definition 
of pre-diabetes; for the definition of stress 
hyperglycemia: an elevation of FPG ≥7 mmol/L, or 
RPG ≥ 11 mmol/L in a patient without evidence of 
previous diabetes. We used glycosylated hemoglobin 
(HbA1c) value to distinguish between patients with 
stress hyperglycemia and those with previously 
undiagnosed diabetes (an HbA1c value ≥ 6.5% 
indicated pre-existing unrecognized diabetes, 
whereas HbA1c value < 6.5% indicated stress-
induced hyperglycemia). Also, we used the ADA 
recommendations for controlled diabetes (HgbA1C 
<7%), to distinguish between diabetic patients with 
controlled and uncontrolled diabetes. We also used 
the ADA glycemic target for critically ill patients (6.1-
10 mmol/L). If a patient was in this range during 
hospitalization we defined that as a good glycemic 
control as opposite to those patients in whom we 
failed to achieve this target. 
We performed several comparative analyses. 
We compared diabetic versus non diabetic patients. 
We also compared patients with good glycemic 
control versus uncontrolled patients. Based on 
HgbA1C and prediagnosed diabetes we subdivided 
the patients in five groups: three groups without 
known diabetes: non-diabetic (<5.6%), pre-diabetic 
(5.6-6.5%), newly diagnosed diabetic (≥6.5%), and 
two groups of pts. with known diabetes: controlled 
(<7%), and uncontrolled (≥7%). Cardiac event rate 
was analyzed as a function of these glycemic 
variables. 
 
Statistical analysis 
Descriptive and comparative statistics for 
continuous variables with t-test (and non-parametric 
test for small samples), Chi square test for categorical 
variables (Pearson Chi square) and Fisher exact test 
for 2x2 tables and Odds Ratio (with Mantel-Haenszel 
common odds ratio), uni and multivariate logistic 
regression analysis for identifying the predicting 
variables and obtaining the ROC curves. Significance 
was determined at 0.05. 
 
 
Results 
 
The study population consisted of 150 
patients, 93 males and 57 females (overall mean age 
62.9 ± 12.3 years) According to their HgbA1C level, 
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glucose profile and known diabetes patients were 
divided in five groups: Group 0: non-diabetic patients 
(37.3%); Group 1: newly diagnosed pre-diabetes 
(24.7%); Group 2: newly diagnosed diabetes (5.3%); 
Group 3: known diabetes good controlled (14.0%), 
and Group 4: known diabetes uncontrolled (18.7%). 
 
Figure 1: Distribution of patients according to their diabetic status. 
DM indicates diabetes mellitus 
 
Baseline characteristics 
Male patients predominated in our study and 
they were significantly younger in comparison to the 
females (p = 0.003). Female patients were more often 
hypertensive (OR 1.46; CI 1.16-4.98) and had DM 
(OR 1.36; CI 0.99-2.46), while males were more often 
smokers (OR 4.66; CI 2.29-9.45) and had positive 
familial history of coronary artery disease (CAD). We 
didn’t find gender differences in the mean ejection 
fraction, but reduced LV systolic function was more 
often present in females (p = 0.030). Also, no 
significant gender difference was found in CAD 
distribution or PCI outcome. The only significant 
difference in the biochemical parameters between 
genders was found for Hgb which was significantly 
lower in females (p = 0.000), but in the normal range.  
When we made a comparison of these same 
variables between patients with and without DM, we 
found that non DM patients had OR of 2.1 (CI 1.16-
2.40; p = 0.002) for smoking. But, there were no 
significant differences in LV function or in CAD 
distribution or PCI outcome. DM pts had significantly 
higher Tg levels (p = 0.041) and variables of glycemic 
control: HgbA1C and stress glycaemia (p = 0.000 for 
both variables).  
The baseline characteristics of the patients as 
a function of the glycemic metabolism revealed that 
newly diagnosed diabetes was far more frequent in 
females (75%) and pre-diabetes predominated in 
males (77.6%), both groups being significantly older. 
Based on HbgA1C levels we identified 45 out of 101 
patients (44.5%) without known DM to be diabetic 
(7.9%) or prediabetic (36.6%). Mean HgbA1C levels 
were high in newly diagnosed DM, but even higher in 
uncontrolled DM pts. The same was for stress 
glycaemia levels. The highest levels were in new DM 
and uncontrolled known DM, as compared with 
controlled known DM (p = 0.026 and p = 0.001 
respectively).  
Table 1: Baseline characteristics of ACS patients, and 
according to gender 
Variable Total (N) Males (M) Females (F) Significance (p) 
Gender 150 93 (62%) 57 (38%) 0 .000 
Age 62 .9±12 .3 60 .6±11 .8 66 .7±12 .4 0 .003 
HTA 85 (56 .7%) 44 (47 .3%) 41 (71 .9%) 0 .002 (OR for female 
gender 1 .46; CI 1 .16-1 
.98; p=ns) 
HLP 22 (14 .7%) 13 (14 .0%) 9 (15 .8%) 0 .468 
Diabetes 49 (32 .7%) 25 (26 .9%) 24 (42 .1%) 0 .025 (OR for female 
gender  1 .36; CI 0 .99-
2 .46; p=0 .034) 
Family history  48 (32%) 34 (36 .6%) 14 (24 .6%) 0 .088 (OR for male 
gender 1 .77 . p=ns) 
Smoking 89 (59 .3%) 68 (73 .1%) 21 (36 .8%) 0 .000 (OR  for male 
gender 4 .66; CI 2 .29-9 
.45; p=0 .000) 
Type of ACS     
1 - APNS 
2 - NSTEMI 
3 - STEMI inferior 
4 - STEMI anterior 
24 (16%) 
12 (8%) 
57 (38%) 
57 (38%) 
14 (15 .0%) 
8 (8 .6%) 
35 (37 .6%) 
38 (40 .9%) 
10 (17 .5%) 
6 (10 .5%) 
22 (38 .6%) 
19 (33 .3%) 
0 .704 
LV function     
EF (%) 51 .3±8 .1 51 .9±8 .8 50 .2±6 .8 0 .215 
LV systolic function 
Normal (EF >50%) 
Reduced (EF <50%) 
Severely reduced 
(<30%) 
 
83 (55 .3%) 
59 (39 .3%) 
8 (5 .3%) 
 
59 (63 .4%) 
29 (31 .2%) 
5 (5 .4%) 
 
24 (42 .1%) 
30 (52 .6%) 
3 (5 .3%) 
 
0 .030 
LV diastolic dysfunction 65 (43 .3%) 41 (44 .1%) 24 (42 .1%) 0 .474 
CA 
SINTAX score 
132 (88%) 
15 .6±8 .1 
83 (89 .2%) 
15 .2±8 .4 
49 (85 .9%) 
16 .2±7 .4 
0 .184 
0 .470 
TIMI score before 
treatment 
0 
1 
2 
3 
 
 
63 (47 .7%) 
7 (5 .3%) 
7 (5 .3%) 
55 (41 .7%) 
 
 
38 (45 .8%) 
2 (2 .4%) 
5 (6 .0%) 
38 (45 .8%) 
 
 
25 (51 .0%) 
5 (10 .2%) 
2 (4 .1%) 
17 (34 .7%) 
 
 
0 .184 
TIMI score after 
treatment 
0 
1 
2 
3 
 
 
8 (6 .1%) 
 
4 (3 .0%) 
120 (90 .9%) 
 
 
5 (6 .0%) 
 
2 (2 .4%) 
76 (91 .6$) 
 
 
3 (6 .1%) 
 
2 (4 .1%) 
44 (89 .8%) 
 
 
0 .863 
Blood analyses 
Hgb 
BUN 
Creatinine 
Na 
K 
 
14 .1±1 .8 
7 .1±4 .5 
95 .7±72 .6 
137 .5±4 .5 
4 .3±0 .7 
 
14 .5±1 .6 
6 .8±4 .6 
90 .1±41 .5 
137 .9±3 .4 
4 .3±0 .6 
 
13 .3±1 .7 
7 .6±4 .4 
104 .8±105 .2 
136 .7±5 .8 
4 .2±0 .8 
 
0 .000 
0 .288 
0 .229 
0 .127 
0 .474 
Lipid profile 
Tg 
HDL chol 
LDL chol 
Lp(a) 
 
1 .8±0 .8 
1 .2±0 .4 
3 .3±1 .2 
35 .0±33 .2 
 
1 .7±0 .8 
1 .1±0 .4 
3 .3±1 .2 
33 .9±34 .4 
 
1 .8±0 .9 
1 .2±0 .3 
3 .4±1 .1 
36 .9±31 .5 
 
0 .495 
0 .270 
0 .585 
0 .592 
Glycemic parameters 
Stress glycaemia 
 
HgbA1C 
 
No glycemic 
control* 
 
10 .3±6 .6 
(range 4-45) 
6 .4±1 .5 
(range 3 .5-11 
.9) 
28 (26%) 
 
9 .5±5 .9 
 
6 .2±1 .3 
 
16 (21 .5%) 
 
11 .6±7 .4 
 
6 .7±1 .8 
 
12 (33 .3%) 
 
0 .061 
 
0 .067 
 
0 .352 (ns) 
In-hospital CE 
Malignant 
arrhythmia (1) 
Acute heart failure 
(2) 
Shock cardiogenic 
(3) 
GIT bleeding (4) 
CV insult (6) 
In-stent thrombosis 
(7) 
Cardiac death (5) 
31 (20 .7%) 
 
10 (6 .6%) 
 
5 (3 .3%) 
 
5 (3 .3%) 
 
5 (3 .3%) 
4 (2 .7%) 
2 (1 .3%) 
11 (7 .3%) 
20 (21 .5%) 
 
 
 
 
 
 
 
 
 
 
8 (8 .6%) 
11 (19 .3%) 
 
 
 
 
 
 
 
 
 
 
3 (5 .3%) 
0 .458 (ns) 
 
 
 
 
 
 
 
 
 
 
0 .338 (ns) 
Length of 
hospitalization 
4 .5±3 .0 4 .3±2 .7 4 .9±3 .4 0 .252 (ns) 
Legend: *glycemic control (range of glycaemia during hospitalization >10 mmoll/L; ACS-
Acute Coronary Syndrome; HTA-arterial hypertension; HLP-hyperlipidemia; ACS- acute 
coronary syndrome; APNS-unstable angina; NSTEMI-non ST-segment elevation 
myocardial infarction; STEMI-ST-segment elevation myocardial infarction; EF-ejection 
fraction; CA-coronary angiography; CE-cardiac events; CV-cerebro-vascular; GIT-gastro-
intestinal tract. 
 
Smoking was the only risk factor that 
significantly differed between groups. The smallest 
proportion of smokers was among pts with controlled 
DM. Newly diagnosed DM had the worst biochemical 
parameters: low Hgb (p < 0.05 in comparison to all 
groups), high BUN and creatinine as renal function 
parameters. But there were no significant differences 
in the Lp fractions. No significant difference was found 
for LV function, as opposite to CAD distribution, which 
was found to be the worst in newly diagnosed DM pts 
who had worst TIMI flow before treatment, but no 
intergroup differences were found after the PCI 
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procedure. The mean hospitalization time was 4.5 ± 
3.0 days with the longest duration in pts with newly 
diagnosed DM (p = 0.035). The event rate was 20.7% 
during the hospital treatment with in-hospital mortality 
rate of 7.3%.  
Table 2: Baseline characteristics of ACS patients in 
accordance of the presence of known DM 
Variable All pts DM pts NDM pts Sig (p) 
Risk factors 
HTA 
 
HLP 
Family history 
smoking 
 
85 (56 .7%) 
 
 
 
22 (14 .7%) 
48 (32%) 
89 (59 .3%) 
 
32 (65 .3%) 
 
 
 
7 (14 .3%) 
17 (34 .7%) 
20 (40 .8%) 
 
53 (52 .5) 
 
 
 
15 (14 .8%) 
31 (30 .7%) 
69 (68 .3%) 
 
 
ns (OR for HTA in 
DM pts 1 .7; CI 0 .84-
3 .45; p=ns) 
 
ns 
ns 
0 .001 (OR for NDM 
smokers is 2 .1; CI 1 
.16-2 .4; p=0 .002) 
LV function     
EF (%) 51 .3±8 .1 51 .0±7 .3 51 .4±8 .5 0 .802 (ns) 
LV systolic function 
Normal (EF >50%) 
Reduced (EF <50%) 
Severely reduced (<30%) 
 
83 (55 .3%) 
59 (39 .3%) 
8 (5 .3%) 
 
25 (51 .0%) 
23 (46 .9%) 
1 (2 .1%) 
 
58 (57 .4%) 
36 (35 .6%) 
7 (7%) 
 
0 .247 (ns) 
LV diastolic dysfunction 65 (43 .3%) 21 (42 .8%) 44 (43 .6%) 0 .538 (ns) 
CA 
SINTAX score 
132 (88%) 
15 .6±8 .1 
45 (91 .8%) 
16 .5±8 .5 
87 (86 .1%) 
15 .1±7 .9 
0 .184 (ns) 
0 .365 (ns) 
TIMI score before treatment 
0 
1 
2 
3 
 
63 (47 .7%) 
7 (5 .3%) 
7 (5 .3%) 
55 (41 .7%) 
 
23 (55 .5%) 
2 (4 .4%) 
3 (6 .7%) 
17 (37 .8%) 
 
40 (45 .9%) 
5 (5 .7%) 
4 (4 .6%) 
38 (43 .7%) 
 
0 .862 (ns) 
TIMI score after treatment 
0 
1 
2 
3 
 
8 (6 .1%) 
 
4 (3 .0%) 
120 (90 .9%) 
 
5 (11 .1%) 
 
2 (4 .4%) 
38 (84 .4%) 
 
3 (3 .4%) 
 
2 (2 .3%) 
82 (94 .4%) 
 
0 .162 (ns) 
Blood analyses 
Hgb 
BUN 
Creatinine 
Na 
K 
 
14 .1±1 .8 
7 .1±4 .5 
95 .7±72 .6 
137 .5±4 .5 
4 .3±0 .7 
 
14 .0±1 .6 
7 .5±4 .6 
105 .3±106 .7 
135 .2±5 .4 
4 .4±0 .7 
 
14 .1±1 .9 
6 .9±4 .5 
91 .0±48 .2 
138 .5±3 .6 
4 .2±0 .6 
 
0 .678 (ns) 
0 .455 (ns) 
0 .260 (ns) 
0 .000 
0 .103 (ns) 
Lipid profile 
Tg 
HDL chol 
LDL chol 
Lp(a) 
 
1 .8±0 .8 
1 .2±0 .4 
3 .3±1 .2 
35 .0±33 .2 
 
1 .9±0 .9 
1 .1±0 .2 
3 .4±1 .1 
38 .8±35 .3 
 
1 .7±0 .8 
1 .2±0 .4 
3 .3±1 .2 
33 .2±32 .3 
 
0 .041 
0 .483 (ns) 
0 .615 (ns) 
0 .334 (ns) 
Glycemic parameters 
Stress glycaemia 
HgbA1C 
 
10 .3±6 .6 
6 .4±1 .5 
 
14 .8±7 .9 
8 .2±4 .5 
 
8 .2±4 .5 
5 .7±0 .8 
 
0 .000 
0 .000 
In-hospital CE 
Cardiac death (5) 
31 (20 .7%) 
11 (7 .3%) 
11 (22 .4%) 
5 (10 .2%) 
20 (19 .8%) 
6 (5 .9) 
0 .431 (ns) 
0 .266 (ns) 
Length of hospitalization 4 .5±3 .0 4 .4±2 .8 4 .5±3 .1 0 .881 (ns) 
 
Although the number of patients in each 
group was small and the groups were unequal, the 
highest death rate was registered among patients with 
newly diagnosed and uncontrolled known DM. When 
we analyzed the duration of hospital treatment as a 
function of in-hospital morbidity and mortality we 
registered a significant difference (4.2 ± 2.5 for pts 
without, versus 5.7 ± 4.2 for pts with, p = 0.009), as 
shown in Figure 2.  
 
Figure 2: Length of hospitalization as a function of in-hospital 
morbidity 
Table 3: Baseline characteristics of ACS patients according to 
glycose metabolism 
Variable       
HgbA1C (%) 
 
0-Non DM 1-Newly 
diagnosed 
pre-DM 
2-Newly 
diagnosed 
DM 
3- Known 
DM good 
controlled 
Known DM 
uncontrolled 
Sig (p) 
Pearson Chi 
Square or 
ANOVA and 
Post hoc Tukey 
N 56 (37 .3%) 37 (24 .7%) 8 (5 .3%) 21 (14 .0%) 28 (18 .7%) 0 .000 
HgbA1C 5 .2±0 .5 5 .9±0 .2 7 .6±1 .1 6 .2±0 .5 9 .0±1 .2 0 .000 
for all except 
1 vs 3 p=ns 
Stress 
glycaemia 
7 .1±2 .2 7 .8±2 .9 
 
17 .7±9 .9 
 
11 .3±4 .7 
 
17 .4±8 .8 0 .000 for 
0 and 1 vs 2 .4; 
0 .012 for 0 vs 3 
0 .026 for 2 vs 3  
0 .001 for 3vs 4 
Age 59 .3±13 .6 
 
65 .4±11 .9 
 
71 .7±8 .7 
 
65 .2±9 .2 
 
62 .5±11 .5 0 .023 
0 .054 for 0 vs 2 
Gender 
  
  
 
15(26 .8%) 
41(73 .2%) 
 
12 (32 .4%) 
25 (77 .6%) 
 
6 (75%) 
2 (25%) 
 
13 (61 .9%) 
8 (38 .1%) 
 
11 (39 .3%) 
17 60 .7%) 
 
0 .010 
Smoking 
% in the group 
46 (82%) 20 (54%) 3 (37 .5%) 7 (33 .3%) 13 (46 .4%) 0 .000 
Diastolic 
dysfunction 
22(14 .7%) 18 (12%) 4 (2 .7%) 9 (6%) 12 (8 .5%) 0 .917 (ns) 
Hgb 14 .4±1 .4 
 
14 .2±1 .9 
 
11 .9±2 .9 
 
14 .1±1 .5 
 
13 .9±1 .7 0 .008 
0 vs 2 0 .003 
1 vs 2 0 .009 
2 vs 3 0 .023 
3 vs 4 0 .050 
BUN 
 
Creatinine 
Na 
 
 
 
 
K 
6 .3±4 .1 
 
90 .7±56 .5 
138 .5±3 .1 
 
 
 
 
4 .3±0 .6 
6 .9±4 .2 
 
86 .7±29 .9 
138 .1±3 .8 
 
 
 
 
4 .1±0 .5 
11 .1±6 .2 
 
113 .6±52 .6 
140 .7±4 .9 
 
 
 
 
3 .9±0 .9 
7 .3±3 .1 
 
124 .0±152 
.4* 
135 .0±7 .1 
 
 
 
4 .3±0 .6 
7 .6±5 .5 
 
91 .3±50 .6 
135 .3±3 .9 
 
 
 
 
4 .5±0 .8 
0 .074 
0 vs 2 0 .040 
0 .332 (ns) 
0 .000 
0 vs 3 0 .014 
0 vs 4 0 .012 
2 vs 3 0 .014 
2 vs 4 0 .016 
0 .094 (ns) 
LP profile 
Tg 
HDL chol 
LDL chol 
Lp(a) 
 
1 .7±0 .8 
1 .1±0 .5 
3 .2±1 .3 
37 .2±32 .9 
 
1 .6±0 .7 
1 .3±0 .4 
3 .4±1 .1 
23 .9±18 .4 
 
2 .0±1 .1 
1 .2±0 .3 
3 .5±0 .7 
47 .9±61 .38 
 
1 .8±0 .8 
1 .2±0 .2 
3 .3±1 .1 
32 .3±19 .9 
 
2 .1±1 .1 
1 .1±0 .3 
3 .5±1 .1 
43 .7±43 .2 
 
0 .128 (ns) 
0 .181 (ns) 
0 .897 (ns) 
0 .107 (ns) 
EF (%) 51 .7±9 .0 52 .1±7 .2 45 .6±9 .0 51 .7±6 .9 51 .3±8 .1 0 .314 (ns) 
Syntax score 14 .0±7 .9 15 .9±7 .7 20 .8±5 .9 15 .3±9 .3 17 .3±7 .9 0 .261 (ns) 
TIMI flow 
before 
treatment 
1 .8±1 .4 1 .1±1 .4 0 .2±0 .5 1 .6±1 .5 1 .1±1 .4 0 .031 
TIMI flow after 
treatment 
2 .9±0 .4 2 .9±0 .5 2 .4±1 .3 2 .6±0 .9 2 .6±0 .9 0 .214 
CE 
CD 
(in the group) 
11 (19 .63%) 
4 (7 .1%) 
5 (13 .5%) 
0 
4 (50%) 
2 (25%) 
2 (9 .5%) 
0 
9 (32 .1%) 
5 (17 .8%) 
0 .056 
0 .012 
Hospitalization 
(days) 
4 .5±2 .7 3 .9±2 .8 7 .2±5 .3 4 .1±2 .3 4 .7±3 .1 0 .072 
1 vs 2 0 .035 
Legend: 0-non diabetic patients HgbA1C ≤ 5,7%; 1-newly diagnosed prediabetes HgbA1C 
5,7 to 6,5%; 2-newly diagnosed diabetes HgbA1C >6,5%; 3-known diabetes good 
controlled (HgbA1C ≤7%); 4-known diabetes uncontrolled (HgbA1C >7%); BUN-blood 
urea; LP-lipoprotein; CE-cardiac event; CD-cardiac death. *there were 3 pts. on chronic 
hemodialysis treatment what is the reason for higher mean and high SD. 
 
Aiming to identify predictors of cardiac events 
(CE) and cardiac death (CD), and to define the role of 
glycemic metabolism variables as CE predictors, we 
performed a univariate binary logistic regression (for 
categorical variables) and a linear analysis (for 
continuous variables) and identified advanced age 
and smoking, Hgb (lower), BUN (higher), creatinine 
(higher) and HDL cholesterol of the risk factors, 
reduced LV systolic function and angiographic 
variables: Syntax score and TIMI flow. We also 
identified stress glycaemia, HgbA1C (as a definer of 
newly diagnosed and uncontrolled known DM) and 
established glycoregulation as significant predictors of 
CE and CD.  
In an attempt to identify independent 
predictors of cardiac events we performed a 
multivariate logistic regression analysis using the 
variables found as predictors in the univariate 
analysis. Variables included in the prediction model 
were: age, cigarette smoking, EF as a continuous and 
a categorical variable (three categories: 0-normal, 1-
mildly /moderately reduced; 2-severely reduced), TIMI 
flow and Syntax score, Hgb, BUN, creatinine, stress 
glycaemia, glucoregulation, and HDL cholesterol. We 
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applied a backward stepwise conditional model with 
Chi square 38.675; sig 0.001, correct prediction 88, 
6%, and at step 10 we identified four independent 
predictors: smoking (Exp(B) 5.945; CI 1.79-19.66); p = 
0.004), EF (%) (beta -0.089; p = 0.007), HDL chol       
(-3.179; p = 0.016), and glycoregulation (yes) (Exp(B) 
0.324 (CI 0.08-1.19; p = 0.060). 
Table 4: Univariate predictors of in-hospital cardiac events 
(binary logistic regression) 
Variable Chi square sig Wald Exp (B) sig 
Age 6 .819 0 .009 Beta .045  0 .012 
Smoking 4 .825 0 .028 4 .742 .409 0 .029 
Stress glycaemia 9 .574 0 .002 Beta .087  0 .004 
HgbA1C  
 Group 2 
 Group 4 
8 .596 0 .072  
3 .114 
3 .158 
 
.330 
.222 
 
0 .078 
0 .076 
HgbA1C (>6 .5%) 7 .496 0 .006 Beta -1.161  0 .006 
Glycoregulation* 6 .474 0 .011 6 .803 .303 0 .009 
Hgb 14 .141 0 .000 Beta -.425  0 .000 
BUN 25 .548 0 .000 Beta .242  0 .000 
Creatinine 4 .962 0 .026 Beta .005  0 .037 
HDL cholesterol 9 .443 0 .002 Beta -2.444  0 .007 
Reduced EF (<50%) 14 .978 0 .001 7 .847 .107 0 .005 
EF (%) 9 .677 0 .002 Beta -.076  0 .003 
TIMI flow before PCI 
 TIMI 0 
 TIMI 1 
0 .113 0 .028  
6 .486 
3 .562 
 
5 .417 
6 .933 
 
0 .011 
0 .059 
Syntax score 5 .030 0 .025 Beta .065  0 .026 
Legend: glycoregulation (Gl range 6-10mmol/L); BUN-blood urea; PCI-percutany coronary 
intervention 
 
We applied the same model for the prediction 
of cardiac death only without angiographic variables 
because 4 cardiac deaths occurred in patients who 
did not underwent coronary angiography (Chi square 
47.419; sig 0.000, correct prediction 94.7%) at step 6 
we identified three independent predictors: EF (beta   
-0.368; p = 0.014), BUN (beta 0.267; p = 0.002), and 
stress glycaemia (beta 0.146; p = 0.060). 
During the analysis of the performance 
capability of stress glycaemia to identify/predict 
cardiac events and cardiac deaths we found that both 
in-hospital morbidity and mortality in ACS patients are 
highly predictable and defined by the stress glycaemia 
level. 
 
Figure 3: Prediction of CE with stress glycaemia (ROC curve) 
 
The classification of performance capability of 
stress glycaemia on cardiac events presented with a 
ROC curve found an area under the curve of 0.716 
and p = 0.000. 
The classification of performance capability of 
stress glycaemia on cardiac death presented with a 
ROC curve found an area under the curve of 0.850 
and p = 0.000. 
 
Figure 4: Prediction of CD with stress glycaemia (ROC curve) 
 
 
Discussion 
 
Prevalence of newly diagnosed diabetes 
In our study we found only 5% of the patients 
to present with newly diagnosed diabetes and nearly 
25% of pre-diabetes, which means that nearly one 
third of the patients with acute coronary syndrome had 
previously unrecognized impaired glycose 
metabolism.  
Abdullatef in his study of the Qatarian 
population with acute coronary syndrome reports a 
very high prevalence of newly diagnosed diabetes in 
21%, pre-diabetes in 14%, and stress hyperglycemia 
in 10% of the patients, predominantly males and 
elderly. Deane and Horowitz reported that the 
prevalence of newly diagnosed diabetes in critically ill 
patients is around 10-15%. Gardner reported that 
admition hyperglycemia was found in 41% of the 
elderly patients with acute coronary syndrome [2, 3, 
8]. 
Elderly patients and males predominated . as 
found in the majority of the studies. But it seems that 
in terms of newly diagnosed diabetes, the prevalence 
in our study was smaller, for what we don’t have any 
logical explanation, except the small study sample. 
Similar prevalence of 5% reports Chih in the 
Australian cohort of patients with acute coronary 
syndrome [9]. 
One third of the patients were with known 
diabetes. Similar numbers have been reported for 
hospitalized patients because of acute coronary 
syndrome  and 10-15% for critically ill patients treated 
in ICU [3]. 
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Hyperglycemia and newly diagnosed diabetes 
and in-hospital morbidity/mortality 
The association of diabetes with increased 
risk of complications in patients with acute coronary 
syndrome is a well-known fact. But, less established 
are the facts that stress hyperglycemia is caring out 
an increased risk of complications, not only in diabetic 
but also in patients with previously unknown diabetes. 
Simon et co-workers reported a positive linear 
association between the degree of hyperglycemia and 
the mortality in patients with acute coronary 
syndrome, independently of the presence of 
confirmed diabetes [10].  
In our study we found that stress 
hyperglycemia was more pronounced in newly 
diagnosed diabetics, as compared to patients with 
well controlled known diabetes. The occurrence of 
complications was associated with stress 
hyperglycemia and failure to achieve good glycemic 
control during hospitalization, not with the presence of 
diabetes. Patients with newly diagnosed diabetes had 
the longest hospitalization time and the highest in-
hospital morbidity and mortality rates. Although we 
had a small sample size of newly diagnosed DM 
patients, the death rate in these was 25% and 18% in 
known uncontrolled diabetes. 
Hyperglycemia is an even more significant 
predictor of complications as compared with diabetes 
per se. Patients with stress hyperglycemia with no 
previous history of diabetes have worse clinical 
outcome compared to those with pre-existing diabetes 
with a comparable degree of hyperglycemia. The 
impact of hyperglycemia on the clinical outcome 
depends of several factors such as: the intensity of 
hyperglycemic response, the underlying disease, the 
co-morbidities, the caloric intake and the risk of 
infection. Patients with stress hyperglycemia had a 
higher mortality rate and longer hospital stay 
compared to those with known diabetes and those 
with normoglycaemia [2, 4-7, 11]. 
Points to be remembered: Routine testing for 
glicolizated Hgb seems reasonable in patients 
admitted due to ACS in all patients hospitalized 
because of ACS. It helps us to identify diabetic 
patients yet unidentified. Second, even more 
important goal, is to establishe a good glycemic 
control in both cohorts of patients, newly diagnosed 
and known DM, in order to decrease in-hospital 
complications and length of hospitalization and 
increase survival of patients treated because of acute 
coronary syndrome.  
Limitations: One of the major limitations of the 
study is the small sample size. For these types of 
studies a bigger number of participants are needed, 
and of course long term follows up studies. 
In conclusion, we identified high prevalence of 
previously unknown pre-diabetes and diabetes in ACS 
patients. Stress hyperglycemia and failure to achieve 
good glycemic control during the hospital treatment 
were found to be independent predictors of in-hospital 
morbidity and mortality. 
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